Pharma: Clinic Roundup
ViiV Healthcare, of Brentford, UK, and Shionogi & Co. Ltd., of Osaka, Japan, said initial results indicated that once-daily dolutegravir, an integrase inhibitor, demonstrated noninferiority to twice-daily raltegravir in the SPRING-2 study in treatment-naïve HIV-1 patients.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST